Effects of Epalrestat combined with Pancreatic kininogenase in treatment of patients with diabetic peripheral neuropathy
Objective:To observe effects of Epalrestat combined with Pancreatic kininogenase in the treatment of patients with diabetic peripheral neuropathy.Methods:A prospective study was conducted on 80 patients with diabetic peripheral neuropathy admitted to the hospital from August 2020 to August 2023.According to the random number table method,they were divided into study group and control group,40 cases in each group.The control group was treated with Pancreatic kininogenase enteric-coated tablets,while the study group was treated with Epalrestat on the basis of that of the control group.The clinical efficacy,the Toronto clinical scoring system(TCSS)score,the levels of inflammatory indexes[C-reactive protein(CRP),procalcitonin(PCT)and interleukin-6(IL-6)],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 95.00%,which was significantly higher than 77.50%in the control group,and the difference was statistically significant(P＜0.05).3 days after the treatment,the TCSS scores of neurological symptoms,nerve reflex,sensory function and the serum CRP,PCT and IL-6 levels in the two groups were lower than those 3 days before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05).During the treatment,there was no significant difference in the incidence of adverse reactions such as dry mouth,headache and gastrointestinal discomfort between the two groups(P＞0.05).Conclusions:Epalrestat combined with Pancreatic kininogenase in the treatment of the patients with diabetic peripheral neuropathy can improve the total effective rate of treatment and reduce the TCSS scores and the inflammatory factor levels.Moreover,it is superior to simple Pancreatic kininogenase treatment.
NETL
NSTL
万方数据
